Current medicine, such as PDE5 inhibitors, can successfully target the NO–GC–cGMP signaling for treatment of a lot of vascular diseases such as pulmonary hypertension, angina pectoris, and erectile dysfunction (25). This evidence concerns the gene PDE5A and angina pectoris.